International Survey of Acute Coronavirus Syndromes-COVID-19

NCT ID: NCT05188612

Last Updated: 2025-03-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In response to the COVID-19 crisis, ISACS-TC has promoted a new registry of the existing and further centers of the same geographic areas to support clinical research to prevent, and treat the COVID-19 illness. These efforts are made possible by the generous contributions of clinical research volunteers in some of the countries participating to the prior acute coronary syndrome network.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To address existing gaps in knowledge on CVD among European countries at different income levels, a collaboration of outcomes-oriented researchers from the University of Bologna partnered with Central and East European (CEE) countries researchers to conduct the International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC) investigating underlying threats in patients' CVD health status (NCT01218776).

In response to the COVID-19 crisis, ISACS-TC has promoted a new registry of the existing and further centers of the same geographic areas to support clinical research to prevent, and treat the COVID-19 illness. These efforts are made possible by the generous contributions of clinical research volunteers in some of the countries participating to the prior acute coronary syndrome network.

Scientific and clinical evidence is evolving on the effects of COVID-19, which can affect multiple organ systems. As, so the COVID-19 pandemic underscores the urgent need for coordination, collaboration, and information-sharing among researchers worldwide. Researchers of many disciplines have, therefore, joined the ISACS-TC investigators to build a multi-disciplinary registry investigating the impact of COVID-19.

Projects should be mainly focused on topics related to:

1. The impact of COVID-19 infection on patients who have attended any health care center (within hospital beds), and who have been discharged or have died at the time of the evaluation. The main objective of this task is to carefully characterize the clinical profile of patients infected with COVID-19 in order to develop a simple prognostic clinical score allowing rapid logistic decision making such as discharge with follow-up, referral to provisional hospitals, or admission to hospital centers with advanced equipment or specialized procedures and techniques. A secondary objective of this retrospective analysis is to evaluate the risk-adjusted influence of prior evidence-based treatments and comorbidities on patients infected with the disease.
2. The second issue relates to the long-term health consequences after COVID-19 infection. Early reports suggest residual effects of SARS-CoV-2 infection, such as fatigue, dyspnea, chest pain, cognitive disturbances, arthralgia, and decline in quality of life. However, the evidence is still scarce. Prior studies did not take into account the vast majority of patients with a mild course of the infection. As well, the definition of the post-acute COVID-19 timeline is evolving. Today we may summarize the post-acute COVID-19 syndrome into two categories:

* subacute or ongoing symptomatic COVID-19, which includes symptoms and abnormalities present from 4-12 weeks beyond acute COVID-19;
* chronic or post-COVID-19 syndrome, which includes symptoms and abnormalities persisting or present beyond 12 weeks of the onset of acute COVID-19 and not attributable to alternative diagnoses. Systematic study of sequelae after recovery from acute COVID-19 is needed to develop an evidence-based multidisciplinary team approach for caring for these patients, and to inform research priorities.

One trained physician will critically review the patients' reported symptoms and will assess SARS-CoV-2 IgG at each visit. In addition, wherever needed, the investigators will investigate the daily living status of survivors of COVID-19 using telephone interview questionnaires including Activity Daily Living (ADL), Self-rating Depression Scale (SDS), and New York Heart Association (NYHA) functional class.

* Sponsor: Raffaele Bugiardini (Principal Investigator; PI) - University of Bologna
* Co-PI Investigator (Clinical Research): Olivia Manfrini (University of Bologna)
* Co-PI Investigator (Translational Research): Lina Badimon (IR-Hospital de la Santa Creu i Sant Pau, UAB, Barcelona)
* Collaborator: Associazione Per La Ricerca Cardiologica, Roma

National Investigators:

Bosnia and Herzegovina: Local PI: Mirza Dilic (Clinical Center University of Sarajevo)

Croatia: Local PI: Davor Miličić (University Hospital Center Zagreb)

Other Investigators:

* Marijan Pašalić (University Hospital Center Zagreb)
* Petra Mjehović (University Hospital Center Zagreb)

Italy: Local PI: Stefano Nava (University of Bologna)

Other Investigators:

* Gaetano Caramori (University of Messina)
* Antonio David, (University of Messina)
* Giuseppe Mancuso (University of Messina)
* Maria Laura Vega Pitao (University of Bologna)
* Giulia Panzuti (University of Bologna)
* Edina Cenko (University of Bologna)
* Maria Bergami (University of Bologna)
* Marialuisa Scarpone (University of Bologna)
* Antonio Spanevello (IRCCS Maugeri)
* Fabio Angeli (IRCCS Maugeri)
* Dina Visca (IRCCS Maugeri)
* Martina Zappa (IRCCS Maugeri)
* Paolo Emilio Puddu (Associazione Per La Ricerca Cardiologica, Roma)

Macedonia: Local PI: Sasko Kedev and Marija Vavlukis (University "Ss. Cyril and Methodius")

Other Investigators:

* Lidija Poposka (University Clinic of Cardiology)
* Milena Stefanovic (University Clinic of Infectious Diseases)
* Ilir Demiri (University Clinic of Infectious Diseases) Romania: Local PI: Maria Dorobantu (Emergency Clinical Hospital of Bucharest) Other Investigators: Oana Fronea Gheorghe (Emergency Clinical Hospital of Bucharest)

Serbia: Local PI: Marija Zdravkovic (Hospital Medical Center Bezanijska kosa, Belgrade), Zorana Vasiljevic (University of Belgrade)

Other Investigators:

* Nebojsa Ladjevic, Clinic for Anesthesia, Covid Hospital Batajnica, Belgrade
* Radmilo Jankovic (Clinical Center Nis)
* Goran Loncar (Institute for Cardiovascular Diseases Dedinje)
* Ratko Lasica (Clinical Center of Serbia)
* Miodrag Petrović (Institute for Cardiovascular Diseases Sremska Kamenica, Novi Sad)
* Vlada Vukomanovic (Clinical Hospital Center Dragiša Mišković Belgrade)
* Dubravka Rajic (Clinical Center of Serbia)
* Ana Uscumlic (Clinical Center of Serbia)
* Sanja Stankovic (Clinical Center of Serbia)

Spain: Local PI: Teresa Padro (IR-Hospital de la Santa Creu i Sant Pau, UAB, Barcelona)

Other Investigators:

* Guiomar Mendieta ( CNIC, Madrid)
* Rosa Suades (IR-Hospital de la Santa Creu i Sant Pau, UAB, Barcelona)
* Gemma Vilahur (IR-Hospital de la Santa Creu i Sant Pau, UAB, Barcelona)

United Kingdom: Local PI: Charalambos Antoniades (Oxford University)

Other Investigators:

* Maria Lyasheva (University of Oxford)
* Lucy Kingham (University of Oxford)
* Christos Kotanidis (University of Oxford)
* Cheng Xie (University of Oxford)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Male

Non-interventional patient registry

Observational (registry)

Intervention Type COMBINATION_PRODUCT

Observational (Patient Registry)

Female

Non-interventional patient registry

Observational (registry)

Intervention Type COMBINATION_PRODUCT

Observational (Patient Registry)

Elderly

Non-interventional patient registry

Observational (registry)

Intervention Type COMBINATION_PRODUCT

Observational (Patient Registry)

Hypertension

Non-interventional patient registry

Observational (registry)

Intervention Type COMBINATION_PRODUCT

Observational (Patient Registry)

Diabetes

Non-interventional patient registry

Observational (registry)

Intervention Type COMBINATION_PRODUCT

Observational (Patient Registry)

Dyslipidemias

Non-interventional patient registry

Observational (registry)

Intervention Type COMBINATION_PRODUCT

Observational (Patient Registry)

Smoking

Non-interventional patient registry

Observational (registry)

Intervention Type COMBINATION_PRODUCT

Observational (Patient Registry)

Kidney Disease

Non-interventional patient registry

Observational (registry)

Intervention Type COMBINATION_PRODUCT

Observational (Patient Registry)

Heart Diseases

Non-interventional patient registry

Observational (registry)

Intervention Type COMBINATION_PRODUCT

Observational (Patient Registry)

Vascular diseases

Non-interventional patient registry

Observational (registry)

Intervention Type COMBINATION_PRODUCT

Observational (Patient Registry)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational (registry)

Observational (Patient Registry)

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years (male or female)
* Patients admitted to any hospital center with a confirmed diagnosis of COVID-19 infection.

Exclusion Criteria

• Underage or not able to give informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Associazione Per La Ricerca Cardiologica (Roma)

UNKNOWN

Sponsor Role collaborator

University of Bologna

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Raffaele Bugiardini

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Olivia Manfrini, MD

Role: STUDY_DIRECTOR

University of Bologna

Lina Badimon, PhD

Role: STUDY_DIRECTOR

IR-Hospital de la Santa Creu i Sant Pau, UAB, Barcelona

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Bologna

Bologna, Bologna, Italy

Site Status RECRUITING

IR-Hospital de la Santa Creu i Sant Pau, UAB

Barcelona, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Raffaele Bugiardini, MD

Role: CONTACT

+39 051 347290

Olivia Manfrini, MD

Role: CONTACT

+39 051 2143778

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Olivia Manfrini

Role: primary

Lina Badimon

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Bugiardini R, Nava S, Caramori G, Yoon J, Badimon L, Bergami M, Cenko E, David A, Demiri I, Dorobantu M, Fronea O, Jankovic R, Kedev S, Ladjevic N, Lasica R, Loncar G, Mancuso G, Mendieta G, Milicic D, Mjehovic P, Pasalic M, Petrovic M, Poposka L, Scarpone M, Stefanovic M, van der Schaar M, Vasiljevic Z, Vavlukis M, Vega Pittao ML, Vukomanovic V, Zdravkovic M, Manfrini O. Sex differences and disparities in cardiovascular outcomes of COVID-19. Cardiovasc Res. 2023 May 22;119(5):1190-1201. doi: 10.1093/cvr/cvad011.

Reference Type BACKGROUND
PMID: 36651866 (View on PubMed)

Bergami M, Manfrini O, Nava S, Caramori G, Yoon J, Badimon L, Cenko E, David A, Demiri I, Dorobantu M, Fabin N, Gheorghe-Fronea O, Jankovic R, Kedev S, Ladjevic N, Lasica R, Loncar G, Mancuso G, Mendieta G, Milicic D, Mjehovic P, Pasalic M, Petrovic M, Poposka L, Scarpone M, Stefanovic M, van der Schaar M, Vasiljevic Z, Vavlukis M, Vega Pittao ML, Vukomanovic V, Zdravkovic M, Bugiardini R. Relationship Between Azithromycin and Cardiovascular Outcomes in Unvaccinated Patients With COVID-19 and Preexisting Cardiovascular Disease. J Am Heart Assoc. 2023 Jul 18;12(14):e028939. doi: 10.1161/JAHA.122.028939. Epub 2023 Jul 14.

Reference Type DERIVED
PMID: 37449568 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ISACS-COVID-19

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Survey of COVID-19 Infection
NCT05706064 COMPLETED
Post COVID-19 Condition
NCT05531773 RECRUITING